Mecasermin for the treatment of Rett Syndrome: a systematic review
Authors:
- Fernanda Cristina Poscai RibeiroFRFernanda Cristina Poscai Ribeiro
- Maria Luiza AlvesMAMaria Luiza Alves
- Alice Campos MenesesAMAlice Campos Meneses
- Áleff Mascarenhas SilvaÁSÁleff Mascarenhas Silva
- Sabrine Zambiazi da SilvaSSSabrine Zambiazi da Silva
- Fabiana Khauam MarangoniFMFabiana Khauam Marangoni
- Kleber Fernando PereiraKPKleber Fernando Pereira
- 1 November 2025
- journal article
- review article
- Published by Springer Nature in neurogenetics
- Vol. 26 (1) , 1-9
Abstract
Mecasermin, a recombinant analogue of insulin‑like growth factor 1 (IGF‑1), is under investigation as a potential therapy for Rett syndrome (RTT), a neurodevelopmental disorder resulting from mutations in the MECP2 gene. In this systematic review, we assessed the impact of mecasermin on the full spectrum of RTT severity by screening relevant clinical studies identified through MeSH‑based database queries. Evidence indicates that IGF‑1 administration may help preserve social engagement and cognitive function in RTT, although autonomic control and behavioral outcomes have been inconsistent, and electroencephalographic alterations display considerable heterogeneity. Moreover, transcriptomic analyses have uncovered discrete gene‑expression signatures in molecularly defined patient subgroups, suggesting that genetic background modulates therapeutic response. These findings highlight the promise of mecasermin for ameliorating specific RTT features while underscoring the necessity of larger, rigorously designed trials to refine treatment regimens and implement stratified, patient‑specific approaches.Keywords
This publication has 30 references indexed in Scilit:
- Trofinetide: a pioneering treatment for Rett syndromeTrends in Pharmacological Sciences, 2023
- Trofinetide: First ApprovalDrugs, 2023
- Synaptic plasticity during systems memory consolidationNeuroscience Research, 2022
- Treating Rett syndrome: from mouse models to human therapiesMammalian Genome, 2019
- Placebo‐controlled crossover assessment of mecasermin for the treatment of Rett syndromeAnnals of Clinical and Translational Neurology, 2018
- The role of Insulin-Like Growth Factor 1 (IGF-1) in brain development, maturation and neuroplasticityNeuroscience, 2016
- Expression of nuclear Methyl-CpG binding protein 2 (Mecp2) is dependent on neuronal stimulation and application of Insulin-like growth factor 1Neuroscience Letters, 2016
- Clinical manifestations and stages of rett syndromeMental Retardation and Developmental Disabilities Research Reviews, 2002
- Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2Nature Genetics, 1999
- Neurotrophins regulate dendritic growth in developing visual cortexNeuron, 1995